Bristol-Myers Squibb/$BMY
Bristol-Myers Squibb falls after report Trump administration readies 100% tariffs on drug imports for companies lacking pricing agreements.
13 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bristol-Myers Squibb
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Ticker
$BMY
Sector
Primary listing
NYSE
Employees
32,500
Headquarters
Website
BMY Metrics
BasicAdvanced
$122B
17.23
$3.46
0.29
$2.49
4.23%
Price and volume
Market cap
$122B
Beta
0.29
52-week high
$62.89
52-week low
$42.52
Average daily volume
13M
Dividend rate
$2.49
Financial strength
Current ratio
1.255
Quick ratio
1.076
Long term debt to equity
241.673
Total debt to equity
254.982
Dividend payout ratio (TTM)
71.52%
Interest coverage (TTM)
7.95%
Profitability
EBITDA (TTM)
19,116
Gross margin (TTM)
72.62%
Net profit margin (TTM)
14.64%
Operating margin (TTM)
31.21%
Effective tax rate (TTM)
24.36%
Revenue per employee (TTM)
$1,480,000
Management effectiveness
Return on assets (TTM)
10.29%
Return on equity (TTM)
40.33%
Valuation
Price to earnings (TTM)
17.225
Price to revenue (TTM)
2.515
Price to book
6.57
Price to tangible book (TTM)
-5.42
Price to free cash flow (TTM)
9.438
Free cash flow yield (TTM)
10.60%
Free cash flow per share (TTM)
6.315
Dividend yield (TTM)
4.18%
Forward dividend yield
4.23%
Growth
Revenue change (TTM)
-0.22%
Earnings per share change (TTM)
-178.38%
3-year revenue growth (CAGR)
1.45%
10-year revenue growth (CAGR)
11.27%
3-year earnings per share growth (CAGR)
5.46%
10-year earnings per share growth (CAGR)
14.04%
3-year dividend per share growth (CAGR)
4.37%
10-year dividend per share growth (CAGR)
5.27%
What the Analysts think about BMY
Analyst ratings (Buy, Hold, Sell) for Bristol-Myers Squibb stock.
BMY Financial Performance
Revenues and expenses
BMY Earnings Performance
Company profitability
BMY News
AllArticlesVideos
Global pharma companies that have publicly announced Trump drug pricing agreements
Reuters·14 hours ago
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Business Wire·5 days ago
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
Business Wire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Bristol-Myers Squibb stock?
Bristol-Myers Squibb (BMY) has a market cap of $122B as of April 03, 2026.
What is the P/E ratio for Bristol-Myers Squibb stock?
The price to earnings (P/E) ratio for Bristol-Myers Squibb (BMY) stock is 17.23 as of April 03, 2026.
Does Bristol-Myers Squibb stock pay dividends?
Yes, the Bristol-Myers Squibb (BMY) stock pays dividends to shareholders. As of April 03, 2026, the dividend rate is $2.49 and the yield is 4.23%. Bristol-Myers Squibb has a payout ratio of 71.52% on a trailing twelve-month basis.
When is the next Bristol-Myers Squibb dividend payment date?
The next Bristol-Myers Squibb (BMY) dividend payment is scheduled for May 01, 2026.
What is the beta indicator for Bristol-Myers Squibb?
Bristol-Myers Squibb (BMY) has a beta rating of 0.29. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.